Table 3.
Ceftazidime/Avibactam | Outcome | |||||||
---|---|---|---|---|---|---|---|---|
First Author and Year | Bacterium | Mechanism of Resistance | Dosage | Antibiotics Combination | Treatment (days) | Surgical Treatment | Clinical Cure | Microbiological Cure |
Cani E, 2017 [8] | K. pneumoniae | N/A | 2.5 g t.i.d. | Amikacin | 42 | Yes | Yes | N/A |
Rico-Nieto A, 2018 [9] | K. pneumoniae | OXA-48 | 2.5 g t.i.d. | Colistin | 56 | Yes | Yes | N/A |
De León-Borrás R, 2018 [10] | K. pneumoniae | KPC | N/A | Amikacin, polymyxin B |
42 | No | Yes | N/A |
Rodríguez-Núñez O, 2018 [11] | P. aeruginosa | N/A | N/A | Tobramycin, ciprofloxacin |
34 | Yes | No | Yes |
Mittal J, 2018 [12] | K. pneumoniae | NDM, OXA-181 |
2.5 g t.i.d. | Aztreonam | 46 | Yes | Yes | Yes |
Schimmenti A, 2018 [13] | K. pneumoniae | KPC | 2.5 g t.i.d. | None | 14 | Yes | Yes | Yes |
Alamarat ZI, 2020 [14] |
P. aeruginosa
K. pneumoniae |
NDM-1 KPC |
2.5 g t.i.d. | Aztreonam | 14 | Yes | No | N/A |
Meschiari A, 2021 [15] |
P. aeruginosa
K. pneumoniae P. aeruginosa |
N/A KPC N/A |
2.5 g q.i.d. 2.5 g t.i.d. |
Aztreonam Aztreonam |
42 56 |
Yes Yes |
Yes Yes |
N/A N/A |
Mularoni A, 2021 [16] | P. aeruginosa | VIM-1 | 2.5 g t.i.d. | Amikacin, aztreonam |
42 | Yes | Yes | Yes |
Ji Z, 2021 [17] | K. pneumoniae | N/A | 2.5 g t.i.d. | None | 21 | Yes | Yes | Yes |
Eskenazi A, 2022 [18] | K. pneumoniae | OXA-48 | 2.5 g t.i.d. | Moxifloxacin, phage |
88 | Yes | Yes | Yes |
Racenis K, 2022 [19] | P. aeruginosa | KPC | 2.5 g t.i.d. | Phage | 15 | Yes | No | No |
Rubnitz ZA, 2022 [20] | C. sedlakii | NDM | 2.5 g t.i.d. | Aztreonam | 42 | Yes | No | Yes |
Present cases, 2023 |
P. aeruginosa
P. aeruginosa P. aeruginosa |
N/A N/A N/A |
2.5 g t.i.d. 2.5 g t.i.d. 2.5 g t.i.d. |
None Fosfomycin Amikacin |
42 42 42 |
No Yes Yes |
Yes Yes Yes |
N/A N/A N/A |
N/A, not available.